Navigation Links
Mayo Clinic study finds apathy and depression predict progression from mild cognitive impairment
Date:7/12/2010

ROCHESTER, Minn. -- A new Mayo Clinic study found that apathy and depression significantly predict an individual's progression from mild cognitive impairment (MCI), a disorder of the brain that affects nerve cells involved in thinking abilities, to dementia, including Alzheimer's disease and Lewy body dementia. The study was presented at the International Conference on Alzheimer's Disease in Honolulu on July 11, 2010.

"An important area of study is the identification of biomarkers and clinical predictors for the progression from normal cognition to mild cognitive impairment and mild cognitive impairment to dementia," says Yonas E. Geda, M.D., a Mayo Clinic neuropsychiatrist and the study's lead investigator. "We knew from previous smaller studies that neuropsychiatric symptoms like depression, apathy and agitation seem to predict progression from mild cognitive impairment to dementia, so we set out to look at this hypothesis in a population-based setting with a larger sample size."

Depression and apathy are neuropsychiatric symptoms that are often difficult to distinguish, according to Dr. Geda. Depression causes changes in mood, thinking, physical well-being and behavior, while apathy is loss of motivation without associated feelings of being depressed or blue.

As part of the Mayo Clinic Study of Aging, Dr. Geda and a team of Mayo Clinic researchers identified 358 individuals with mild cognitive impairment and used a questionnaire to collect data on depression and apathy. Then, they prospectively followed individuals to the outcome of dementia (a median of 2.8 years). Among 87 individuals with depression, 30 (34.5 percent) developed dementia. Of the 271 individuals without depression, 59 (21.8 percent) developed dementia. Among 60 individuals with apathy, 22 (36.7 percent) developed dementia. Of the 298 individuals without apathy, 67 (22.5 percent) developed dementia.

After adjusting for age, gender and education, the researchers found that the individuals with mild cognitive impairment and depression had a 66 percent increased risk of developing dementia than those individuals with mild cognitive impairment without depression. Likewise, the individuals with mild cognitive impairment and apathy had a 99 percent increased risk of developing dementia than those individuals with mild cognitive impairment without apathy.

"These findings highlight the importance of thoroughly evaluating newly-diagnosed patients with mild cognitive impairment for neuropsychiatric symptoms. The next step is to conduct a study to find out if treatment of depression or apathy in MCI may delay the onset of dementia," says Dr. Geda. "This delay could have a huge impact on the quality of life for individual patients and their families, not to mention the broad public health implications of delaying the societal and economic burden of dementia. In fact, a previous biostatistics study from our colleagues at Johns Hopkins indicated that delaying dementia by a mere one year could reduce the prevalence of Alzheimer's disease by nearly 800,000 million fewer cases in 2050."


'/>"/>

Contact: Elizabeth Rice
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. The West Clinic Joins Cancer Clinics of Excellence (CCE)
2. Stethoscope App gives iPhone New Clinical Skills
3. Mayo Clinic responsible for $22 billion in economic impact, including $9.6 billion in Minnesota
4. Sunquest Introduces Integrated Clinical Environment Physician Portal Solution in US
5. Almac Launches New STEMS System to Transform Temperature Controlled Shipment Monitoring in Clinical Trials
6. Clinical trial underway: Miniature ultrasound device could revolutionize pain relief
7. Sunquest Completes System-Wide Implementation at Cleveland Clinic Hospital Laboratories
8. Michael J. Fox Foundation Awards $1.1 Million For Clinical Trial of Transdermal Nicotine as Disease-Modifying Treatment For Parkinsons
9. NOVAVAX Presents Positive Clinical Results at The World Health Organization Conference, Geneva, Switzerland
10. UCLA Health System Presents: How to Successfully Implement a Clinical Portal
11. International Merchant Advisors CEO Mel Roseman to Discuss New Medical Marijuana Clinics Live on CBS Radio Networks Big Biz Show February 22, 2010 at 1:40 pm PST
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2016)... California (PRWEB) , ... May 30, 2016 , ... ... easy to use inside of FCPX," said Christina Austin - CEO of Pixel ... exclusively for use within Final Cut Pro X. Choose from abstract transitions to ...
(Date:5/29/2016)... , ... May 29, 2016 , ... Whole Health Supply ... their new KlipPro KP-240L clipper is available to the public. This is an unusual ... substantially wider than the average clipper. , Everything about this product is concentrated on ...
(Date:5/28/2016)... Hartford, CT (PRWEB) , ... May 28, 2016 , ... After a year and a ... report it was an extraordinary event. The Multiple Pathways of Recovery Conference was held ... from across the country and the United Kingdom came together to explore the many pathways ...
(Date:5/27/2016)... ... 27, 2016 , ... W.S. Badger Co. Inc ., the maker of ... recognized as one of the best small businesses for new dads by Fatherly, the ... small businesses providing progressive benefits to new parents on the organization’s 2016 Best ...
(Date:5/27/2016)... ... May 27, 2016 , ... In response to meager public ... unaware of the plight of aphasia. In collaboration with the American Aphasia Association, ... , The link between stroke and aphasia is relatively unknown, but through collaboration ...
Breaking Medicine News(10 mins):
(Date:5/27/2016)... -- Hutchison China MediTech (Chi-Med) (HCM) ... highly lucrative global oncology and immunology markets. HCM ... or best-in-class tyrosine kinase inhibitor (TKI) drugs, some ... HCM,s profitable Chinese healthcare business continues to benefit ... of the mid-to-late-stage pipeline during 2016-17 (including US ...
(Date:5/26/2016)... A key trend that will ... of new treatments. Cardax, a development stage life sciences ... therapy is expected to fulfil large unmet medical needs ... studies to develop new treatments for osteoarthritis. One such ... in osteoarthritis are being investigated, and early trials of ...
(Date:5/25/2016)... According to a new market ... 4D), by Therapeutic Area (Oncology, Cosmeceutical/Plastic Surgery), by Application ... Manufacturers, Hospitals/ Clinics) - Forecast to 2021", published by ... for the forecast period of 2016 to 2021. This ... 2021 from USD 117.3 Million in 2016, at a ...
Breaking Medicine Technology: